Anne C Armstrong

9PUBLICATIONS
99CO-AUTHORS
Molecular targetsSite-based writingApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

|Sep 30, 2025
To the editor.

Anne Armstrong, Rebecca Bowen, Paula Briggs

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

|May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

Jean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz

|Nov 08, 2023
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.

Hans Wildiers, Anne Armstrong, Eveline Cuypere

|May 18, 2022
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.

Geoffrey J Lindeman, Tharu M Fernando, Rebecca Bowen

Pageof 2

Frequent Collaborators

1 joint publications

Robert K Hastings

1 joint publications

Mark Rutherford

1 joint publications

Jaqueline A Shaw

1 joint publications

Nigel Bundred